We Work for Health | Washington

06/05/2026

Tune in to the Making Medicine Podcast to hear federal leaders speak to:
🔹 The “pill penalty” and the EPIC Act
🔹 How the IRA changed biotech investment incentives
🔹 China’s growing role in global biotech
🔹 The importance of bipartisan problem-solving

https://www.youtube.com/watch?v=dywPjU4RJlw

06/03/2026

"Europe believes it has a right to American taxpayer generosity. For too long, they have underinvested in their own defense while expecting Washington to foot the bill."

puts the U.S. at a competitive disadvantage: https://amgreatness.com/2026/05/25/europes-freeloading-days-are-over-america-demands-reciprocity/

06/01/2026

"Half of all new medicines are developed in the United States, yet Americans pay two to three times more for those medicines than people in other developed countries.

If it sounds unfair, that’s because it is."

disincentivizes R&D: https://pjmedia.com/ashley-herzog/2026/05/26/trump-must-end-germanys-healthcare-freeloading-n4953265

05/29/2026

Curious about the impact of on your employer-sponsored health plan?

Calculate the cost in Washington state here: https://www.nationalalliancehealth.org/340b-calculator/ #

Access helpful documents, infographics, webinars, newsletters, playbooks, and more designed to help organizations move health equity and value forward.

05/27/2026

Tune in for a discussion on MFN policy and efforts to reduce U.S. drug prices by linking them to prices in other high-income countries, all while maintaining overall industry revenues through higher prices abroad: https://www.youtube.com/watch?v=OeGr32tEdmE

05/22/2026

"Price controls hurt German patients by restricting the availability of new drugs. German patients only had access to about 60% of medicines launched globally between 2014 and 2021.

American patients could access 85% of those medicines."

in action: https://www.thewellnews.com/opinions/europes-drug-policies-are-stalling-innovation/

05/20/2026

"Drugmakers disproportionately rely on revenue from the United States to sustain research and development. While patients abroad often pay cut-rate prices, Americans pay far more for the same meds."

isn't a good deal for the U.S.:

Germany's drug price controls shift costs to Americans, raising U.S. healthcare expenses unfairly.

05/18/2026

: China’s rapidly growing Phase 1 and 2 pipeline is closing the gap with the U.S., creating global competition in the race to develop the next generation of therapies.

More from the Washington Examiner:

China is pairing domestic price controls with an outward push of innovation, encouraging its firms to compete globally even as it disciplines them at home.

05/15/2026

"Nearly all of America's trading partners use a variety of price controls and non-tariff trade barriers, such as deliberate bureaucratic delays and not-so-subtle threats to invalidate American companies' patent protections."

For months, the Trump administration has floated the idea of a formal investigation into foreign countries' unfair drug pricing practices -- an implicit threat intended to push our allies into proacti

05/13/2026

"It takes roughly $2.7 billion, on average, to successfully bring a drug to market. It’s also risky, as roughly 90% of drugs that enter clinical trials never make it to patients."

won't bolster the innovation economy:

Germany’s approach to drug pricing is a textbook example of how developed nations shift the cost of medical progress onto American patients.